ATI 50002

Drug Profile

ATI 50002

Alternative Names: A 301; ATI 50002

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rigel Pharmaceuticals
  • Developer Aclaris Therapeutics
  • Class Skin disorder therapies
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alopecia areata
  • Preclinical Vitiligo

Most Recent Events

  • 07 Nov 2017 Phase-II clinical trials in Alopecia areata in Australia (Topical)
  • 31 Oct 2017 Phase-II clinical trials in Alopecia areata (Topical) in USA (NCT03315689)
  • 08 Aug 2017 Aclaris Therapeutics plans a second phase II dose-ranging trial of ATI 50002 for Alopecia areata in USA (Topical) in the second half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top